Plainville, Mass.
Thermo Fisher Scientific is planning to build a $180 million viral vector development and manufacturing facility in Plainville, Mass. Featuring flexible and scalable production suites, the 290,000-sf structure will leverage advanced digital technologies to enhance operational efficiencies. Enabling Thermo Fisher to more than double its commercial manufacturing capacity for vaccines and gene therapies, the project will include offices, warehouse spaces, and an onsite engineering lab for the creation of turnkey production platforms. Construction is expected to begin in the third quarter of 2020 with completion expected in 2022.
Source
